Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27861298 | 0.86 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28578164 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7855992 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1901344 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1343527 | 0.80 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26660361 | 0.80 | CYP4F2 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL322149 | 0.79 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28451530 | 0.77 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3714482 | 0.76 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2534149 | 0.76 | CA12 (0.65) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119191448-A | Slaughter house sewage treatment method and water treatment agent | 河北惠泽智能水处理科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| CN-119191448-A | Slaughter house sewage treatment method and water treatment agent | 河北惠泽智能水处理科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-RE48731-E1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3722296-A2 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3366293-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110433162-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-12 | — | — | CN | disclosed |
| CN-110403938-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-05 | — | — | CN | disclosed |
| CN-104902895-B | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 德西费拉制药有限责任公司 | 2019-03-29 | — | — | CN | disclosed |
| EP-3366293-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| EP-0001041-A2 | Alpha(pyridonecarboxylamino)-alpha substituted acetamido penicillins and -cephalosporins, process for their preparation, their use in pharmaceuticals; pyridones used in the process | SANDOZ AG (CH) | 1979-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | CA12 4868/4885CA1 4708/4885CA2 4370/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | CA12 4868/4885CA1 4708/4885CA2 4370/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | CA12 3039/4885CA1 1904/4885CA2 281/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | CA12 3329/4885CA1 2215/4885CA2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.